Related Experiment Videos
[Interferon alpha and gamma in the treatment of renal cell carcinoma]
1Department of Urology, Tsukuba University School of Medicine.
Abstract:
We report 31 cases of renal cell carcinoma treated with interferon. Indicators defined as bidimensionally measurable mass were present in 20 cases, which included 19 cases with metastatic lesions and one case with primary site who did not receive nephrectomy. Treatment were performed with interferon-gamma in 9 cases, and with interferon-alpha in 14 cases. Of them, 3 cases received alpha-interferon following gamma-interferon treatment. Remained 11 cases had no evidence of disease after radical nephrectomy or surgical removal of metastatic lesions, and received interferon-alpha as post operative adjuvant therapy. In 18 evaluable cases, one case (6%) showed minor response; 8 cases (44%) no change and 9 cases (50%) progressive disease. Survival rates (Kaplan-Meier's method) of minor response and no change cases at 1, 2 years were 89%, 59%. Those of progressive disease cases were 22% and 11%, respectively. Of 11 cases received post operative adjuvant therapy, recurrence was observed in four cases (36%) with the mean follow up period of 11 months. Frequent side effects were fever (62%), leukocytopenia (56%) anorexia (38%), fatigue (26%). Efficacy of interferon to metastatic renal cell carcinoma in this study is limited. Further studies are required to determine the benefit of post operative adjuvant therapy with interferon.
Insights
Interferon therapy showed limited efficacy for metastatic renal cell carcinoma, with most patients experiencing no change or progressive disease. Further research is needed to confirm benefits of post-operative adjuvant interferon therapy.
Area of Science:
- Oncology
- Immunotherapy
Context:
- Renal cell carcinoma (RCC) is a significant health concern.
- Interferon (IFN) has been explored as a treatment for metastatic RCC.
- Limited data exists on the efficacy of IFN-gamma and IFN-alpha in RCC treatment.
Purpose:
- To evaluate the efficacy and safety of interferon therapy in patients with renal cell carcinoma.
- To assess the outcomes of interferon-gamma and interferon-alpha in metastatic RCC.
- To investigate the role of adjuvant interferon therapy after surgery for RCC.
Summary:
- This study analyzed 31 renal cell carcinoma cases treated with interferon (IFN).
- Interferon-gamma and interferon-alpha were administered to patients with measurable disease or as adjuvant therapy post-surgery.
- Treatment yielded limited response rates (6% minor response, 44% no change, 50% progressive disease) and significant side effects, suggesting limited efficacy.
Impact:
- The findings indicate that interferon therapy has limited efficacy in treating metastatic renal cell carcinoma.
- Adjuvant interferon therapy post-surgery showed a 36% recurrence rate.
- Further studies are required to establish the definitive role and benefit of interferon in RCC management.